Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study

• Published in: The American heart journal 2023-05, Vol.259, p.30-41
• Main Authors: Gibson, C. Michael, Steinhubl, Steven, Lakkireddy, Dhanunjaya, Turakhia, Mintu P., Passman, Rod, Jones, W. Schuyler, Bunch, T. Jared, Curtis, Anne B., Peterson, Eric D., Ruskin, Jeremy, Saxon, Leslie, Tarino, Michael, Tarakji, Khaldoun G., Marrouche, Nassir, Patel, Mithun, Harxhi, Ante, Kaul, Simrati, Nikolovski, Janeta, Juan, Stephanie, Wildenhaus, Kevin, Damaraju, C.V., Spertus, John A.
• Format: Article
• Language: English
• Subjects: Adult; Age; Anticoagulants; Apples; Asymptomatic; Atrial Fibrillation - complications; Atrial Fibrillation - diagnosis; Atrial Fibrillation - drug therapy; Cardiac arrhythmia; Cardiovascular diseases; Clinical outcomes; Coronaviruses; COVID-19; Diagnosis; EKG; Electrocardiography; Embolism; Fibrillation; Fruits; Health care access; Health services; Heart; Hemorrhage; Humans; Medical diagnosis; Patient compliance; Randomization; Resource utilization; Smartphones; Smartwatches; Stroke; Thromboembolism; Thromboembolism - diagnosis; Thromboembolism - etiology; Thromboembolism - prevention & control; Wearable technology
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2023.01.004

The impact of using direct-to-consumer wearable devices as a means to timely detect atrial fibrillation (AF) and to improve clinical outcomes is unknown. Heartline is a pragmatic, randomized, and decentralized application-based trial of US participants aged ≥65 years. Two randomized cohorts include adults with possession of an iPhone and without a history of AF and those with a diagnosis of AF taking a direct oral anticoagulant (DOAC) for ≥30 days. Participants within each cohort are randomized (3:1) to either a core digital engagement program (CDEP) via iPhone application (Heartline application) and an Apple Watch (Apple Watch Group) or CDEP alone (iPhone-only Group). The Apple Watch Group has the watch irregular rhythm notification (IRN) feature enabled and access to the ECG application on the Apple Watch. If an IRN notification is issued for suspected AF then the study application instructs participants in the Apple Watch Group to seek medical care. All participants were “watch-naïve” at time of enrollment and have an option to either buy or loan an Apple Watch as part of this study. The primary end point is time from randomization to clinical diagnosis of AF, with confirmation by health care claims. Key secondary endpoint are claims-based incidence of a 6-component composite cardiovascular/systemic embolism/mortality event, DOAC medication use and adherence, costs/health resource utilization, and frequency of hospitalizations for bleeding. All study assessments, including patient-reported outcomes, are conducted through the study application. The target study enrollment is approximately 28,000 participants in total; at time of manuscript submission, a total of 26,485 participants have been enrolled into the study. The Heartline Study will assess if an Apple Watch with the IRN and ECG application, along with application-facilitated digital health engagement modules, improves time to AF diagnosis and cardiovascular outcomes in a real-world environment. ClinicalTrials.gov Identifier: NCT04276441.